The Role of Prostate-Specific Antigen in Prostate Cancer Screening

1. Gretzer MB, Partin AW. Chapter 93. Prostate cancer tumor markers. In: Wein AJ, ed. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: Saunders; 2007;2896-906.Search in Google Scholar

2. Watt KW, Lee PJ, M’Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70. DOI: 10.1073/ pnas.83.10.316610.1073/pnas.83.10.3166Search in Google Scholar

3. Lilja H, Laurell CB. The predominant protein in human seminal coagulate. Scand J Clin Lab Invest. 1985 Nov;45(7):635-41. DOI: 10.3109/0036551850915527110.3109/00365518509155271Search in Google Scholar

4. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979 Sep;17(2):159-63.Search in Google Scholar

5. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980 Dec;40(12):4658-62.Search in Google Scholar

6. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981 Oct;41(10):3874-6.Search in Google Scholar

7. Seamonds B. Reference intervals for prostate-specific antigen. Clin Chem. 1988 Jun;34(6):1366-7.10.1093/clinchem/34.6.1366Search in Google Scholar

8. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909-16. DOI: 10.1056/ NEJM19871008317150110.1056/NEJM198710083171501Search in Google Scholar

9. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988 Apr;139(4):766-72.10.1016/S0022-5347(17)42630-9Search in Google Scholar

10. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991 Sep;37(9):1618-25.10.1093/clinchem/37.9.1618Search in Google Scholar

11. Ambert V. Diagnosticul in cancerul de prostata, Bucuresti, Editura Universitara Carol Davila, Bucuresti. 2011;74-93.Search in Google Scholar

12. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993 Jul;150(1):100-5.10.1016/S0022-5347(17)35408-3Search in Google Scholar

13. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283-90.10.1016/S0022-5347(17)35233-3Search in Google Scholar

14. Stanciu AE. Clinical applications of total PSA and free PSA tumor markers. Rev Romana Med Lab. 2005;1(1):33-7.Search in Google Scholar

15. Dema A, Taban SM, Lazar E, Anderco D, Loghin A, Lazureanu C, et al. Alpha-methylacyl-CoA-racemase expression in variants and unusual patterns of prostate carcinoma. Rev Romana Med Lab. 2011;19(4):319-31.Search in Google Scholar

16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence ofprostate cancer among men with a prostate- specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. DOI: 10.1056/NEJMoa03191810.1056/NEJMoa03191815163773Search in Google Scholar

17. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005 Mar;65(3):549-53. DOI: 10.1016/j.urology. 2004.10.064Search in Google Scholar

18. Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H. Problems, objective, and substance of early detection of prostate cancer. Urologe A. 2010 Feb;49(2):181-9. DOI: 10.1007/s00120-010-2234-710.1007/s00120-010-2234-720180057Search in Google Scholar

19. www.auanet.org/education/guidelines/prostate-cancer- detection.cfmSearch in Google Scholar

20. Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, et al. Prostate specific antigen testing among the elderly--when to stop? J Urol. 2009 Apr;181(4):1606-14; discussion 1613-4. DOI: 10.1016/j.juro.2008.11.11710.1016/j.juro.2008.11.117Search in Google Scholar

21. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909-16. DOI: 10.1056/ NEJM19871008317150110.1056/NEJM198710083171501Search in Google Scholar

22. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997 Aug;50(2):239-43. DOI: 10.1016/S0090-4295(97)00209-410.1016/S0090-4295(97)00209-4Search in Google Scholar

23. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL,Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22-29;267(16):2215-20. DOI: 10.1001/ jama.1992.0348016007303710.1001/jama.267.16.2215Search in Google Scholar

24. Sinescu I, Chibelean C, Cerempei V, Dudu C, Iordache A, Voinea S, et al. Cancerul de prostată. In Sinescu I, Gluck G. Tratat de Urologie, 1st edition, 3rd volume, Editura Medicala, Bucuresti. 2008;2376-8.Search in Google Scholar

25. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. In Guidelines on Prostate Cancer, European Association of Urology Guidelines, Drukkerij Gelderland, Arnhem. 2013;16-17.Search in Google Scholar

26. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989 May;141(5):1076-83.10.1016/S0022-5347(17)41175-XSearch in Google Scholar

27. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994 Dec;152(6 Pt 1):2031-6.10.1016/S0022-5347(17)32299-1Search in Google Scholar

28. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005 Sep 1;104(5):993-1003. DOI: 10.1002/cncr.2126710.1002/cncr.21267Search in Google Scholar

29. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. DOI: 10.1001/jama.279.19.154210.1001/jama.279.19.1542Search in Google Scholar

30. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999 Sep;54(3):517-22. DOI: 10.1016/S0090-4295(99)00153-310.1016/S0090-4295(99)00153-3Search in Google Scholar

31. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer. 1997 Jan 1;79(1):104-9. DOI: 10.1002/(SICI) 1097-0142(19970101)79:1<104::AID-CNCR15>3.0. CO;2-810.1002/(SICI)1097-0142(19970101)79:1<104::AID-CNCR15>3.0.CO;2-8Search in Google Scholar

32. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993 Aug 18;270(7):860-4. DOI: 10.1001/ jama.1993.0351007008204110.1001/jama.270.7.860Search in Google Scholar

33. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimalprostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994 Dec;152(6 Pt 1):2037-42.10.1016/S0022-5347(17)32300-5Search in Google Scholar

34. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011 Nov;60(5):1045-54. DOI: 10.1016/j. eururo.2011.08.003Search in Google Scholar

35. Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Prostate Cancer. 2013 Mar 12;2013:e539680. DOI: 10.1155/2013/53968010.1155/2013/539680361036823577261Search in Google Scholar

36. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. In Guidelines on Prostate Cancer, European Association of Urology Guidelines, Drukkerij Gelderland, Arnhem. 2013;14-15.Search in Google Scholar

37. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ. 2013 Jan;346:f325. DOI: 10.1136/bmj.f325 10.1136/bmj.f325393827623360718Search in Google Scholar